Page 5 - Steven Lydeamore News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Steven lydeamore. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Steven Lydeamore Today - Breaking & Trending Today

Immuron CEO Steven Lydeamore presented at AusBioInvest

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated bi. ....

Steven Lydeamore , Immuron Limited , Chief Executive Officer , Park Hyatt ,

Anatara Lifesciences Limited Company Summary & News ASX:ANR

Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. ....

David Brookes , Steven Lydeamore , Anatara Lifesciences Limited , Company Appendix , Company Stage , Anatara Lifesciences Ltd , Lifesciences Limited , Bowel Syndrome , David Brookes Read Full Article , Annual Report , Read Full Article , Chief Executive Officer , Full Article , Investor Presentation , Successful Piglet Study , Monthly Activities Report , Chair Transition , Non Executive Director , Chairman Read Full Article , Lifesciences Ltd , Progressing Towards First Human Clinical Studies , Asx Anr , Australian Stock Exchange , Sin Au000000anr0 ,

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced. ....

United States , Steven Lydeamore , Mohamed Al Ibrahim , Immuron Limited , Clinical Research Facility Inpatient Unit , Clinical Trial , Principal Investigator Dr Mohamed Al Ibrahim ,

Immuron Announces Travelan® Clinical Study Cohort 2 commences - Immuron (NASDAQ:IMRN)

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the second ....

United States , Steven Lydeamore , Mohamed Al Ibrahim , Immuron Limited , Clinical Research Facility Inpatient Unit , Clinical Trial , Principal Investigator Dr Mohamed Al Ibrahim ,

Immuron achieves record quarterly Travelan® sales

Highlights: Record quarterly Travelan® sales of $1,550,240Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales130% higher than pre-pandemic period Q1, FY20 sales . ....

United States , Steven Lydeamore , International Trade Administration Total , Australian Bureau Of Statistics , Immuron Limited , Therapeutic Goods Administration , South America , Central America ,